ViAqua Therapeutics News
5 articles
growth-positive
ViAqua Therapeutics Raises $8.25M in Funding
ViAqua Therapeutics, a biotechnology company based in Haifa, Israel, has raised $8.25M in funding. The round was led by S2G Ventures and included participation from Rabo Ventures, The Trendlines Group Ltd., Agriline Limited, Nutreco, I-Lab Angels, and Circle Investments LLC. The company plans to use the funds to bring its first product to market, invest in R&D for future products, and prove the platform’s ability to deliver RNA-based solutions at scale. ViAqua has also established a commercial partnership with Skretting, a Nutreco company, to bring the product to the market.
InvestmentPartners
growth-positive
ViAqua Therapeutics Announces $4.3 Million Investment led by S2G Ventures for its RNA-based Aquaculture Health Platform
ViAqua Therapeutics, an Israeli biotech developing an orally administered RNA-particle platform to improve animal health in aquaculture, completed a $4.3 million financing round to commercialize and scale its platform. New and returning investors include S2G Ventures, Thai Union, Agriline, Nutreco, VisVires New Protein, The Trendlines Group and the Technion, plus additional grant funding from the Israeli Innovation Authority. ViAqua’s proprietary production and encapsulation delivery approach targets viral diseases in shrimp—where outbreaks can cause near-total mortality—and aims to reduce the significant global losses from disease. The company plans to scale up production, expand its product pipeline, and pursue commercialization to address aquatic disease challenges while minimizing environmental impact.
Product StageInvestmentPartnersExpand
https://www.businesstimes.com.sg/technology/sg-fund-visvires-new-protein-invests-in-israeli-shrimp-virus-tech-startup-viaqua
growth-positive
Israeli startup silences diseased genes of shrimp to boost their production
Israeli biotechnology startup ViAqua Therapeutics has developed a feeding solution using RNA molecules to inhibit gene expression and neutralize viral infections in shrimp and other aquaculture species. The company received an investment from Nutreco Investments BV and signed a collaboration agreement with Nutrecos aquaculture division, Skretting AS. The funding will support the development of ViAquas first product and help meet registration requirements. The partnership with Nutreco provides an opportunity for ViAqua to develop technologies tailored to the market. Disease prevention, particularly viral infections, is a major challenge in the aquaculture industry.
PartnersInvestment
growth-positive
Dutch Animal Feed Company Nutreco Invests in Medical Aquafarming Startup ViAqua
Dutch animal feed company Nutreco NV has led a funding round in ViAqua Therapeutics, a medical aquafarming startup. ViAqua also signed a joint development and marketing deal with Nutrecos aquafarming subsidiary Skretting AS. The funding will be used to complete the development and testing of ViAquas particle-based matrix for delivering antiviral medication to shrimp.
Partners
